Document Detail


DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
MedLine Citation:
PMID:  22982660     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Genetic polymorphisms that affect DNA repair capacity can modulate the efficacy and toxicity of cytotoxic agents. Therefore, the aim of our study was to evaluate the influence of genetic variability in DNA repair genes on treatment outcome in patients with malignant mesothelioma (MM) treated with gemcitabine-platinum combination chemotherapy.
METHODS: In total, 109 patients with MM were genotyped for 10 polymorphisms in XRCC1, NBN, RAD51, and XRCC3 genes. The influence of selected polymorphisms on tumor response and occurrence of treatment-related toxicity was determined by logistic regression analysis, whereas their influence on survival was estimated by Cox proportional hazards model.
RESULTS: There were no associations between the investigated polymorphisms and tumor response, but we observed a significant association between XRCC1 399Gln allele and reduced overall survival (hazards ratio = 1.70; 95% confidence interval [CI] 1.06-2.73; p = 0.028). Interaction between XRCC1 399Gln allele and C-reactive protein levels revealed that carriers of at least one XRCC1 399Gln allele with C-reactive protein levels above median had significantly shorter overall survival time compared with other patients (12.9 months versus 25.3 months, log-rank p < 0.001). We also observed an association between XRCC1 399Gln and lower frequency of leukopenia (odds ratio [OR] = 0.25; 95% CI 0.09-0.67; p = 0.006), neutropenia (OR = 0.24; 95% CI 0.09-0.68; p = 0.007), and thrombocytopenia (OR = 0.27; 95% CI 0.09-0.84; p = 0.024). In addition, NBN 3474A>C, XRCC3 -316A>G, and Thr241Met polymorphisms showed significant associations with treatment-related toxicity.
CONCLUSIONS: Our results support the hypothesis that DNA repair gene polymorphisms, particularly XRCC1 Arg399Gln, may modify the response to gemcitabine-platinum combination chemotherapy and, for the first time, show this effect in patients with MM.
Authors:
Nina Erčulj; Viljem Kovač; Julija Hmeljak; Alenka Franko; Metoda Dodič-Fikfak; Vita Dolžan
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer     Volume:  7     ISSN:  1556-1380     ISO Abbreviation:  J Thorac Oncol     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-17     Completed Date:  2013-02-14     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  101274235     Medline TA:  J Thorac Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1609-17     Citation Subset:  IM    
Affiliation:
Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Case-Control Studies
Cell Cycle Proteins / genetics
DNA / analysis,  genetics
DNA Repair / genetics*
DNA-Binding Proteins / genetics
Deoxycytidine / administration & dosage,  analogs & derivatives
Female
Follow-Up Studies
Humans
Male
Mesothelioma / drug therapy,  genetics*,  mortality
Middle Aged
Neoplasm Staging
Nuclear Proteins / genetics
Peritoneal Neoplasms / drug therapy,  genetics*,  mortality
Platinum / administration & dosage
Pleural Effusion, Malignant / drug therapy,  genetics*,  mortality
Polymerase Chain Reaction
Polymorphism, Single Nucleotide / genetics*
Prognosis
Rad51 Recombinase / genetics
Survival Rate
Chemical
Reg. No./Substance:
0/Cell Cycle Proteins; 0/DNA-Binding Proteins; 0/NBN protein, human; 0/Nuclear Proteins; 0/X-ray repair cross complementing protein 1; 0/X-ray repair cross complementing protein 3; 7440-06-4/Platinum; 9007-49-2/DNA; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine; EC 2.7.7.-/RAD51 protein, human; EC 2.7.7.-/Rad51 Recombinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resista...
Next Document:  Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung.